Inflazome, which advances University of Queensland and Trinity College Dublin research to develop treatments for inflammation, has been bought by Roche for $448m.
Ireland-based inflammatory disease drug developer Inflazome was acquired by pharmaceutical firm Roche today for €380m ($448m) in an upfront payment, providing an exit to pharmaceutical firm Novartis.
Inflazome is eligible to receive additional milestone payments, but details were not revealed.
Founded in 2016, Inflazome is working on drugs that target inflammasomes, which drive chronic inflammatory conditions ranging from Parkinson’s and Alzheimer’s diseases to asthma, inflammatory bowel disease, chronic kidney disease, cardiovascular disease and arthritis.
The company is…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
